The bar chart illustrates the expenditure on exploration of five pharmaceutical companies in 2012 and 2018 and forecasts the figures for 2030.
Overall, it can be seen that during the whole time period expenses of all companies increased. In addition, organizations forecast the highest spending on research in the future than ever before, especially Novas.
In 2012, research costs of all companies made up less than 10 $bn, only Pharm spent almost 10$bn. Biopharm’s expenses were close to zero. After 6 years, companies spent much more money for research. Novas’ spending was little more than 15 $bn and Flemin was near to this number. Biopharm’s expenditure again was the smallest, just about 5 $bn.
What about estimated numbers for 2030, expected a rise for all companies. Novas forecasts research spending more than 50 $bn. Flemin’s costs would be about 30 $bn and other companies plan to spend about 20-25 $bn in 2030.
